Save up -80% on Palivizumab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Synagis
|$1,491.71||1 vial (0.5ml) 50mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Synagis coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Palivizumab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Palivizumab volume of distribution
Palivizumab is well absorbed following IM injection in infants, reaching concentrations that exceed 40 ug/mL within 2 days after a single 15-mg/kg dose and that peak within 5-7 days after a dose. Following IM injection of 15-mg/kg doses at monthly intervals in pediatric patients 24 months of age and younger without congenital heart disease (CHD), including patients 6 months of age and younger who were born prematurely at 35 weeks’ gestation or less, serum concentrations of palivizumab measured 30 days after administration of a dose (i.e., trough concentrations) averaged 37-49, 57-69, 68-70, 70-72, and 73 ug/mL after the first, second, third, fourth, and fifth doses, respectively.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Palivizumab
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Palivizumab mechanism of action
Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Dosage forms of Palivizumab
|Injection, solution||intramuscular||100 mg/mL|
|Injection, solution||intramuscular||50 mg/.5mL|
|Powder and solvent for solution for injection||Intramuscular use||100 mg|
Indication of Palivizumab
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
Toxicity of Palivizumab
Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. Signs and symptoms may include urticaria, pruritus, angioedema, dyspnea, respiratory failure, cyanosis, hypotonia, hypotension, and unresponsiveness. The relationship between these reactions and the development of antibodies to Synagis is unknown.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Palivizumab on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.